Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-25-096071
Filing Date
2025-10-02
Accepted
2025-10-02 16:15:38
Documents
14
Period of Report
2025-09-28
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm2527808d1_8ka.htm   iXBRL 8-K/A 30627
2 EXHIBIT 10.1 tm2527808d1_ex10-1.htm EX-10.1 12085
6 GRAPHIC tm2527808d1_ex10-1img001.jpg GRAPHIC 9967
  Complete submission text file 0001104659-25-096071.txt   225854

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kala-20250928.xsd EX-101.SCH 3008
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kala-20250928_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kala-20250928_pre.xml EX-101.PRE 22354
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2527808d1_8ka_htm.xml XML 3568
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38150 | Film No.: 251369258
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)